Evidence map›Paper›PMID 35421196›Full record

ArticlePloS one2022

Isolation and characterization of vB_XciM_LucasX, a new jumbo phage that infects Xanthomonas citri and Xanthomonas fuscans.

Vinícius Marquioni, Fernando Pacheco Nobre Rossi, Deborah Cezar Mendonça, Layla Farage Martins, Franklin Behlau, João Carlos Setubal, Aline Maria da Silva, Maria Teresa Marques Novo-Mansur

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Microbial Nanoparticles in Biological Plant Protection.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Isolation of bacteriophages infectingFrontiers in microbiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Vinícius MarquioniDepartamento de Genética e Evolução (DGE), Laboratório de Bioquímica e Biologia Molecular Aplicada (LBBMA), Universidade Federal de São Carlos (UFSCar), São Carlos, São Paulo, Brazil.ORCID 0000-0001-8645-8060
Fernando Pacheco Nobre RossiDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo (USP), São Paulo, São Paulo, Brazil.
Deborah Cezar MendonçaGrupo de Biofísica e Biologia Estrutural "Sérgio Mascarenhas", Instituto de Física de São Carlos, Universidade de São Paulo (USP), São Carlos, São Paulo, Brazil.
Layla Farage MartinsDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo (USP), São Paulo, São Paulo, Brazil.
Franklin BehlauDepartamento de Pesquisa e Desenvolvimento, Fundo de Defesa da Citricultura (Fundecitrus), Araraquara, São Paulo, Brazil.
João Carlos SetubalDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo (USP), São Paulo, São Paulo, Brazil.
Aline Maria da SilvaDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo (USP), São Paulo, São Paulo, Brazil.
Maria Teresa Marques Novo-MansurDepartamento de Genética e Evolução (DGE), Laboratório de Bioquímica e Biologia Molecular Aplicada (LBBMA), Universidade Federal de São Carlos (UFSCar), São Carlos, São Paulo, Brazil.ORCID 0000-0003-0308-6287
Universidade de São Paulo · BRUniversidade Federal de São Carlos · BRFundo de Defesa da Citricultura · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Citrus canker is one of the main bacterial diseases that affect citrus crops and is caused by Xanthomonas citri which affects all citrus species worldwide. New strategies to control citrus canker are necessary and the use of bacteriophages as biocontrol agent could be an alternative. Phages that infect Xanthomonas species have been studied, such as XacN1, a myovirus that infects X. citri. Here we report the isolation and characterization of a new jumbo phage, vb_XciM_LucasX, which infects X. citri and X. fuscans. Transmission electron microscopy allowed classification of LucasX in the Myoviridae family, which was corroborated by its genomic sequencing, annotation, and proteome clustering. LucasX has a 305,651 bp-long dsDNA genome. ORF prediction and annotation revealed 157 genes encoding putative structural proteins such as capsid and tail related proteins and phage assembly associated proteins, however, for most of the structural proteins it was not possible assign specific functions. Its genome encodes several proteins related to DNA replication and nucleotide metabolism, five putative RNA polymerases, at least one homing endonuclease mobile element, a terminase large subunit (TerL), an endolysin and many proteins classified as beneficial to the host. Proteome clustering and phylogeny analyses showed that LucasX is a new jumbo phage having as its closest neighbor the Xanthomonas jumbo phage Xoo-sp14. LucasX presented a burst size of 40 PFU/infected cell of X. citri 306, was completely inactivated at temperatures above 50°C, presented survival lower than 25% after 80 s of exposition to artificial UV light and had practically no tolerance to concentrations above 2.5 g/L NaCl or 40% ethanol. LucasX presented optimum pH at 7 and a broad range of Xanthomonas hosts, infecting twenty-one of the twenty-three strains tested. Finally, the LucasX yield was dependent on the host strain utilized, resulting one order of magnitude higher in X. fuscans C 752 than in X. citri 306, which points out to the possibility of phage yield improvement, an usual challenge for biocontrol purposes.

Indexed as

BacteriophagesCitrusXanthomonasMyoviridaePlant DiseasesProteomeProteome

Identifiers

PMID35421196
PMCPMC9009655
OpenAlexW4224137889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.